Healthcare Sales & Marketing Network News: LICU

Searching News Database: LICU

HSMN NewsFeed - 8 Jan 2026
Seasoned Biotherapeutics Leader Thomas J. Farrell Joins NanoSyrinx as CEO to Advance Nanosyringe-enabled Intracellular Medicines
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Jan 2022
Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 16 Dec 2021
Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Sep 2021
FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 13 Feb 2020
INVO Bioscience Announces Appointment of Inger Britt Carlsson as VP of Medical Affairs
Devices Personnel

HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Oct 2018
Mayne Pharma Acquires FDA-approved halobetasol foam, Complementing US Dermatology Portfolio
Biopharmaceuticals Dermatology Acquisitions

HSMN NewsFeed - 13 Aug 2018
US Food And Drug Administration (FDA) Clears Natural Cycles As The First Digital Method Of Birth Control In The United States
Devices Diagnostics FDA Product Launch

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 16 Jul 2018
MEI Pharma Promotes David M. Urso to Chief Operating Office
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Jun 2018
Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 May 2018
Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
Diagnostics Oncology Reimbursement

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Nov 2017
EMD Serono Receives FDA Approval for New GONAL-f(R) RFF Redi-ject(R) Pen
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 25 Sep 2017
TapImmune Appoints Peter Hoang as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Apr 2017
Sight Sciences Announces Health Canada Approval of the VISCO(TM)360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)
Devices Ophthalmology Regulatory

HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 31 Mar 2017
Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Jan 2017
Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Oct 2016
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Jul 2016
VytronUS, Inc. Raises $49 Million in Series C Financing
Devices Cardiology Venture Capital

HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Mar 2016
FDA-Cleared DigniCap(R) Scalp Cooling System Is Now Available For Women With Breast Cancer At 10 U.S. Cancer Treatment Centers
Devices Oncology Product Launch

HSMN NewsFeed - 17 Feb 2016
Interpace Diagnostics Receives Medicare Coverage For Its ThyraMIR(TM) Micro RNA Gene Expression Classifer
Diagnostics Oncology Reimbursement

HSMN NewsFeed - 12 Jan 2016
Interpace Diagnostics' New Molecular Test for Thyroid Nodules Now Available Through LabCorp
Diagnostics Oncology

HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals

HSMN NewsFeed - 29 Oct 2015
Bellicum Appoints Alan K. Smith as Senior Vice President of Manufacturing
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Oct 2015
CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 7 Oct 2015
Quartet Medicine Completes $23.25 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Apr 2015
VytronUS, Inc. Attracts Industry Veteran John Pavlidis as New President and Chief Executive Officer
Devices Cardiology Personnel

HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Dec 2014
Bellicum Announces New Director, Executive Management Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Aug 2014
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Aug 2014
Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Apr 2014
Epirus and Zalicus Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Venture Capital

HSMN NewsFeed - 27 Mar 2014
Merck Announces Initiation of Phase III Fertility Study with Pergoveris in Poor Ovarian Response Patients
Biopharmaceuticals

HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2014
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 16 Dec 2013
EMD Serono's Redesigned Fertility Pen Available for Distribution in US
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 6 Sep 2013
Osmotica Pharmaceutical Corp. Announces the Appointment of Gene Wright, Pharm.D., Ph.D. as Vice President, Head of Global Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jul 2013
Warp Drive Bio Appoints Co-Founder Gregory Verdine, Ph.D., to Chief Executive Officer; Expands Team with Two Key Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Jan 2013
Watson Acquires Uteron Pharma SA
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Oct 2012
Restoration Robotics, Inc. Appoints New Board Member
Devices Personnel

HSMN NewsFeed - 30 Jul 2012
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
Biopharmaceuticals Oncology Personalized Medicine

HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons

HSMN NewsFeed - 8 Mar 2012
Bellicum Closes $20 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 9 Nov 2011
Merck Launches NEXPLANON(R) (etonogestrel implant) 68 mg in the United States – A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 3 Aug 2011
Restoration Robotics Receives $41 Million in Series C Financing
Devices Dermatology Venture Capital

HSMN NewsFeed - 27 Jun 2011
Ivantis Announces Completion of $17 MM Financing, CE Mark Approval, and Initiation of International Randomized Controlled Trial for Revolutionary Glaucoma Procedure
Devices Ophthalmology Venture Capital

HSMN NewsFeed - 2 Jun 2011
Covidien Announces U.S. 510(k) Clearance and European CE Mark Approval of Parietex(TM) Optimized Composite Mesh
Devices Surgery FDA Regulatory

HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Apr 2011
ARTAS System Receives FDA Clearance for Ground-Breaking Technology Treating Hair Loss
Devices FDA

HSMN NewsFeed - 5 Apr 2011
Covidien Announces Interim Data Showing Single Incision Gall Bladder Surgery with SILS(TM) Port Associated with Improved Cosmetic Outcome Compared to Four-Port Laparoscopic Approach
Devices Surgery

HSMN NewsFeed - 1 Apr 2011
Promius Pharma and Valeant Form Collaboration to Market Cloderm(R) Cream in the United States
Biopharmaceuticals Dermatology Distribution

HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Nov 2010
Accentia Biopharmaceuticals Announces Strategic Agreement with Baxter
Biopharmaceuticals

HSMN NewsFeed - 13 Aug 2010
FDA Grants Approval of ella(R) for Emergency Contraception
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jun 2010
Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments
Devices

HSMN NewsFeed - 1 Jun 2010
Accentia Files Plan of Reorganization
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Jan 2010
Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Sep 2009
Albert Einstein Healthcare Network Performs Region's First Single-Incision Laparoscopic Gastric Banding Surgery
Devices Surgery Gastroenterology

HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jul 2009
Genentech Announces Appointment of Sandra J. Horning, M.D., To Senior Vice President, Global Head, Clinical Development Hematology/Oncology
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jul 2009
ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Jul 2009
Covidien Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement and Innovation
Devices Surgery Group Purchasing

HSMN NewsFeed - 19 Jun 2009
Covidien Features New Devices for Minimally Invasive Surgery and Soft Tissue Repair at ASMBS 2009
Devices Surgery

HSMN NewsFeed - 22 Apr 2009
Covidien Launches SILS(TM) Port Multiple Instrument Access Port
Devices Surgery

HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2009
Covidien Receives FDA Clearance to Market SILS(TM) Port Multiple Instrument Access Port
Devices Surgery FDA

HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2008
Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts
Devices Distribution

HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Aug 2008
Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark
Devices Surgery Regulatory

HSMN NewsFeed - 31 Jul 2008
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2008
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 May 2008
Covidien Receives FDA Clearance to Market Single-Incision Laparoscopic Surgery (SILS(TM)) Kit
Devices Surgery FDA

HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 24 Apr 2008
Veteran Drug Industry Executive to Become President of CTI
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Apr 2008
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2008
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2008
Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2008
SurgiQuest Announces First Procedure Using AirSeal(TM) Access System
Devices Surgery

HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Biopharmaceuticals

HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Feb 2008
HepaLife's Bioartificial Liver Dramatically Reduces Toxic Marker for Acute Liver Failure
Devices

HSMN NewsFeed - 1 Feb 2008
Obagi Medical Products' Solubilized Benzoyl Peroxide Provides Clinically Significant Lesion Reduction for Mild to Moderately Severe Acne
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals

HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2008
Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Devices Dermatology Venture Capital

HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 12 Dec 2007
Cleveland Clinic Surgeons Perform First Single-Port Laparoscopic Colon Resection
Devices Surgery

HSMN NewsFeed - 10 Dec 2007
Cleveland Clinic Surgeon Performs First Single-Port Laparoscopic Radical Prostatectomy and Single-Port Laparoscopic Radical Cystectomy
Devices Urology Surgery

HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2007
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Nov 2007
Tampa Area's First Single Incision Surgical Procedure Performed at University of South Florida
Devices Surgery

HSMN NewsFeed - 31 Oct 2007
Allergan, Inc. Receives FDA Approval for COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Oct 2007
Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Oct 2007
Accentia Biopharmaceuticals Announces Completion of Enrollment in Fast-Tracked Pivotal Phase 3 Clinical Trial of SinuNase for Chronic Sinusitis
Biopharmaceuticals

HSMN NewsFeed - 17 Sep 2007
Surgeons Complete First Ever Single Port Laparoscopic Surgeries
Devices Surgery

HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology

HSMN NewsFeed - 15 Aug 2007
Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis
Biopharmaceuticals

HSMN NewsFeed - 9 Aug 2007
Tikvah Therapeutics Names Jack W. Callicutt Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 18 Jun 2007
Genmab Announces Development Plans for Ofatumumab
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2007
Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
Biovest to File for Accelerated Conditional Approval of BiovaxID
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Favrille Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
NCCN Updates Thyroid Carcinoma Guidelines
Oncology

HSMN NewsFeed - 21 May 2007
Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 May 2007
Accentia Biopharmaceuticals Makes Milestone Payment Based on Fast Tracked Pivotal Phase 3 Study with SinuNase for the Treatment of Chronic Sinusitis
Biopharmaceuticals

HSMN NewsFeed - 8 May 2007
Favrille Appoints Richard Ghalie, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Feb 2007
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 14 Feb 2007
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Feb 2007
ARIAD Grants Second Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Feb 2007
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2007
Corautus Genetics and VIA Pharmaceuticals Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Jan 2007
Obagi Medical Products, Inc. Launches CLENZIderm M.D. Penetrating Acne Therapeutic System
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Jan 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Dec 2006
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
Biopharmaceuticals

HSMN NewsFeed - 19 Dec 2006
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Nov 2006
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Nov 2006
Palomar Announces Patent License Agreement with Cynosure
Devices Licensing

HSMN NewsFeed - 6 Nov 2006
Accentia Biopharmaceuticals Commences Fast-Tracked Phase 3 Clinical Trial of SinuNase for the Treatment of Chronic Sinusitis
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Nov 2006
Corautus Genetics Announces Redirection of Focus and Transition Of Officers
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Oct 2006
New Landmark Study Shows the Use of a BiovaxID Formulation Improves Disease Free survival in 80% of Patients Whose Cancer has Relapsed after Chemotherapy Administered With or Without Rituxan
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Oct 2006
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Oct 2006
ARIAD Grants Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Licensing

HSMN NewsFeed - 11 Oct 2006
Bellicum Pharmaceuticals Announces Commercial Licensing of ARIAD's ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Licensing

HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Jul 2006
Favrille Publishes Data From Phase 2 Clinical Trial Demonstrating Biologic Activity of Lead Product Candidate FavId in Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 24 May 2006
Association Between Molecular Remission and Disease-Free Survival in Non-Hodgkins Lymphoma at Over Nine Years Follow-Up To Be Presented
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2006
FDA Gives Permission to Use Very Sensitive Molecular Evidence of Cancer in BiovaxID Pivotal Phase 3 Clinical Trial
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 May 2006
Genitope Corporation Appoints Dr. Mary Rybak Vice President of Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 May 2006
U.S. FDA Grants Orphan Drug Designation to OXiGENE's Lead Clinical Candidate, Combretastatin A4P (CA4P), for the Treatment of Ovarian Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 May 2006
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 May 2006
Biovest's AutovaxID(TM) Cleared for Commercial Sale
Biopharmaceuticals Devices FDA

HSMN NewsFeed - 8 May 2006
Accentia Biopharmaceuticals Receives FDA Approval for Three Unique Dosage Combination Pain Product ANDAs
Biopharmaceuticals FDA

HSMN NewsFeed - 4 May 2006
Biovest International Announces Addition to Senior Management Team
Biopharmaceuticals Personnel

Return to NewsFeed

Additional items found! 134

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 134 additional stories matching:
LICU
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!